Elan Corporation PLC (ELN)

TEXT SIZE:
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
Letters are not case-sensitive, disregard spaces.
captcha image
This helps us prevent automated registrations and spamming.
G. Kelly Martin , CEO/President/Director
Industry: Healthcare
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME


Overview
News
People
Financials

Company Information

G. Kelly Martin, CEO/President/Director

Treasury Building

Lower Grand Canal Street

Dublin 2,

IE Map it

Phone: 35317094000

Fax: 35317094700

www.elan.com



Overview

A neuroscience-based biotechnology company operates into two business units: Biopharmaceuticals and Elan Drug Technologies.

News From Around the Web
Blogs
powered by  inform

Employees

Number of Employees: 1,610
Revenue per Employee: $358,535

Top Executives

Richard Collier, Executive VP/General Counsel
Dr. Ivan Lieberburg, MD, PhD, Executive VP/Chief Medical Officer
Dr. Allison Hulme, PhD, Divisional Executive VP/Other Corporate Officer

Dr. Menghis Bairu, MD, Senior VP/Other Corporate Officer
Dr. James Callaway, PhD, Senior VP/Other Corporate Officer
Dr. Johannes Roebers, PhD, Senior VP/Other Corporate Officer

Paul V. Breen, Divisional Executive VP
Dr.Ted Yednock, PhD, Executive VP/Other Corporate Officer
Kathleen Martorano, Executive VP, Divisional/Other Corporate Officer

Dr. David W. Feigal, Jr, MD, Other Corporate Officer/Senior VP
Nigel Clerkin, Senior VP, Divisional/Other Corporate Officer/Chief Accounting Officer
Dr. Dale Schenk, PhD, Chief Scientific Officer/Executive VP

Karen S. Kim, Divisional Executive VP

Board of Directors

Jonas Frick, Director
Kieran McGowan, Director
William R. Rohn, Director

Ann Maynard Gray, Director
William F. Daniel, Secretary/Executive VP

Jeffrey Shames, Director
Gary Kennedy, Director
Shane Cooke, Director/CFO/Executive VP/Other Corporate Officer

Giles Kerr, Director
Kyran McLaughlin, Chairman of the Board/Director

Financials

Quarterly
Annual

Income Statement 04/2008 02/2008 11/2007 09/2007
Sales 114.7 Mil. 97.2 Mil. 176.5 Mil. -65.6 Mil.
Gross Operating Profit 100 Mil. 121.1 Mil. 100 K. 168.3 Mil.
Operating Income before D & A (EBITDA) -42.6 Mil. -40.7 Mil. -155.3 Mil. -79.5 Mil.
Total Income Before Interest Expenses (EBIT) -48.9 Mil. -46.3 Mil. -63.4 Mil. -132.8 Mil.
Total Net Income -85.5 Mil. -83.5 Mil. -87.4 Mil. -189.6 Mil.
Basic EPS, Total -0.18 -0.18 -0.19 -0.4
Diluted EPS, Total -0.18 -0.18 -0.19 -0.4

BALANCE STATEMENT 04/2008 02/2008 11/2007 09/2007
Cash and Equivalents 548.9 Mil. 423.5 Mil. 784.8 Mil. 826 Mil.
Total Assets 875.3 Mil. 916.4 Mil. 993.8 Mil. 1.01 Bil.
Total Liabilities 251.6 Mil. NA 263.4 Mil. 200.1 Mil.
Total Capitalization 1.47 Bil. 1.53 Bil. 1.59 Bil. 1.7 Bil.

Cash Flow 04/2008 02/2008 11/2007 09/2007
Net Cash From Continuing Operations -67.3 Mil. NA -108.7 Mil. -59.7 Mil.
Net Cash From Investing Activities 178 Mil. NA -8.5 Mil. -8.5 Mil.
Net Cash From Financing Activities 14.7 Mil. NA -608.6 Mil. -616 Mil.
Net Change in Cash & Cash Equivalents 125.4 Mil. NA -725.8 Mil. -684.6 Mil.

powered by Interactive Data

Income Statement 2008 2007 2006 2005
Sales 337.9 Mil. 112.7 Mil. 115.8 Mil. 96.9 Mil.
Gross Operating Profit 421.5 Mil. 447.7 Mil. 374.5 Mil. 384.8 Mil.
Operating Income before D & A (EBITDA) -180.7 Mil. -131.3 Mil. -217.2 Mil. -213 Mil.
Total Income Before Interest Expenses (EBIT) -285 Mil. -114.3 Mil. -257.5 Mil. -306.4 Mil.
Total Net Income -405 Mil. -267.3 Mil. -383.6 Mil. -394.7 Mil.
Basic EPS, Total -0.86 -0.62 -0.93 -1.01
Diluted EPS, Total -0.86 -0.62 -0.93 -1.01

BALANCE STATEMENT 2008 2007 2006 2005
Cash and Equivalents 423.5 Mil. 1.51 Bil. 1.08 Bil. 1.35 Bil.
Total Assets 916.4 Mil. 1.76 Bil. 1.25 Bil. 1.73 Bil.
Total Liabilities NA 851.5 Mil. 246.6 Mil. 440.3 Mil.
Total Capitalization 1.53 Bil. 1.85 Bil. 2.03 Bil. 2.46 Bil.

Cash Flow 2008 2007 2006 2005
Net Cash From Continuing Operations NA -238.7 Mil. -283.5 Mil. -347.9 Mil.
Net Cash From Investing Activities NA 34.7 Mil. 120.9 Mil. 474.2 Mil.
Net Cash From Financing Activities NA 629.3 Mil. -99.7 Mil. 441.5 Mil.
Net Change in Cash & Cash Equivalents NA 429.9 Mil. -266.9 Mil. 569.4 Mil.

powered by Interactive Data





Related Companies by Market Cap
Company Name
Price
Change
Market Cap
6.29 Bil.
2.03 Bil.
1.39 Bil.
968.78 Mil.

Company Profile Change Request

The data provided in our company profiles comes from third party information providers.

  • If you have a change request regarding a publicly traded company, click here
  • If your request pertains to a private company, click here
Also in Portfolio.com
Most Emailed
Recently Commented